Median PFS was 51 months ( 95 % CI 29-70 ) in the rilotumumab 15 mg/kg group , 68 months ( 45-75 ) in the rilotumumab 75 mg/kg group , 57 months ( 45-70 ) in both rilotumumab groups combined , and 42 months ( 29-49 ) in the placebo group .